GV led the first disclosed round for the anti-viral nasal spray developer, investing $47.2m together with F-Prime Capital, Casdin Capital and Brook Byers.
Netherlands-headquartered anti-viral product developer Leyden Labs has completed a €40m ($47.2m) series A round led by GV, an early-stage investment vehicle for internet and technology conglomerate Alphabet.
The round included F-Prime Capital, a venture capital subsidiary of investment and financial services group Fidelity, in addition to life sciences investment firm Casdin Capital and angel investor Brook Byers.
Leyden is researching the commonalities of viral families in a bid to develop nasal sprays that would hypothetically protect users against multiple viruses…
